BTLA anticorps (PE)

N° du produit ABIN2662567

L’anticorps Hamster arménien Monoclonal anti-BTLA a été validé pour FACS. Il convient pour détecter BTLA dans des échantillons de Souris.

Aperçu rapide pour BTLA anticorps (PE) (ABIN2662567)

Antigène: BTLA (B and T Lymphocyte Associated (BTLA))

Reactivité: Souris

Hôte: Hamster arménien

Clonalité: Monoclonal

Conjugué: Cet anticorp BTLA est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Clone: 6A6

Détail du produit anti-BTLA anticorps (PE)

Purification: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur BTLA

Antigène: BTLA (B and T Lymphocyte Associated (BTLA))

Autre désignation: CD272

Sujet: CD272, also known as B and T lymphocyte attenuator (BTLA), is an Ig superfamily co-inhitory receptor with structural similarity to programmed cell death 1 (PD-1) and CTLA-4. BTLA is expressed on B cells, T cells, macrophages, dendritic cells, NKT cells, and NK cells. Engagement of BTLA by its ligand herpes virus entry mediator (HVEM) is critical for negatively regulating immune response. The absence of BTLA with HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity, enhanced rejection of partially mismatched allografts, an increased CD8+ memory T cell population, increased severity of colitis, and reduced effectiveness of T regulatory cells. BTLA plays an important role in the induction of peripheral tolerance of both CD4+ and CD8+ T cells in vivo. Tolerant T cells have significantly higher expression of BTLA compared with effectors and naive T cells. BTLA may cooperate with CTLA-4 and PD-1 to control T cell tolerance and autoimmunity. It was reported that BTLA may regulate T cell function by binding to B7-H4, but further studies are needed to confirm. The existence of three distinct BTLA alleles has been reported.

Pathways: Cancer Immune Checkpoints